💡 Did you know?
The BSE, founded in 1875, is Asia's oldest stock exchange — it started under a banyan tree on Dalal Street, where the bronze bull stands today.
History
The BSE, founded in 1875, is Asia's oldest stock exchange — it started under a banyan tree on Dalal Street, where the bronze bull stands today.
The BSE, founded in 1875, is Asia's oldest stock exchange — it started under a banyan tree on Dalal Street, where the bronze bull stands today.
Divi's Laboratories Limited is an India-based company, which is engaged in pharmaceutical ingredients (APIs), intermediates and nutraceutical ingredients with predominance in exports. The Company’s products include Bupropion HCl, Capecitabine, Carbidopa, Diltiazem HCl,…
Weekly engine runs — movement reflects the numbers, not analyst opinion.
A decent, steadily growing business, priced for perfection.
Divis Laboratories is scored on the pharma / healthcare framework. It keeps a fat 23.2% of every rupee of sales as net profit. Cash broadly tracks reported profit (CFO/PAT 1.07×). Free cash flow is worth about 0.2% of its market value.
Over the last 3 years revenue compounded at 11%/yr and profit at 12%/yr. Book value has grown 10%/yr. Return on equity is a healthy 15.3%. In the latest quarter profit grew 20% versus the prior quarter.
At 107× earnings, the stock sits at the 100th percentile of its own 3.6-year range — the expensive end of where it has historically traded. Today's price already implies ~30%/yr earnings growth sustained for a decade — a demanding bar. The books come through clean — a forensic grade of A, and Altman puts distress risk in the safe zone.
A plain-English restatement of the figures on this page — rules-based, for education and research context, not investment advice or a recommendation.
| Ratio | Company | Sector | Read |
|---|---|---|---|
| P/E | 93.53 | — | — |
| P/B | 16.32 | 4.1 | worse |
| EV/EBITDA | 61.17 | 19.33 | worse |
| ROE | 15.32 | — | — |
| ROCE | 19.56 | 14.41 | better |
| ROA | 14.6 | — | — |
| Quick Ratio | 3.5 | 4.8 | worse |
| Peer | P/E | P/B | ROE |
|---|---|---|---|
| Sun Pharmaceutical Industries | 40.6 | 5.0 | 13.8% |
| Torrent Pharmaceuticals | 85.9 | 9.8 | 11.4% |
| Laurus Labs | 94.7 | 20.8 | 22.1% |
Revenue has grown every year across all 4 financial years shown. 11% CAGR over 3 years — steady double-digit compounder.
Operating margins have been stable around 31% — no major structural shift.
ROE at 15% — a respectable return on shareholder capital. ROE powered by fat margins — the hallmark of a high-quality franchise with pricing power. Low variance across years — a predictable business that earns steadily on its equity base.
12% EPS CAGR — this is the rate at which each share's claim on earnings is compounding.
Operating cash flow has been positive every year — the business generates real cash, not just accounting profit. Heavy investing spend every year, but operations generate enough to cover it — the business self-funds its growth. Financing outflows in consecutive years — balance-sheet discipline through debt repayment or dividends.
When operating cash keeps pace with reported profit, earnings are cash-backed; a persistent shortfall is a quality flag.
Revenue rose 5% sequentially — momentum is building. Run-rate stepping up — recent quarters average 10% above earlier ones.
Profit jumped 20% QoQ — check if this is operating leverage or a one-off item. Quarterly net margins are expanding (24% → 29%) — profitability per rupee of revenue is improving.
How today's P/E compares to the stock's own historical range. Dashed line = the 3.6y median.
Promoter holding at 51.9% — majority control intact.
Produced by a rules-based engine over licensed exchange fundamentals — every sentence above is derived from the numbers shown, no analyst or AI opinion involved. Education and research context, not investment advice. We are not SEBI-registered as an Investment Adviser or Research Analyst.